About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Profile
Schools
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Scientometrics
Avg Impact Factor
h-index
g-index
★★
Articles
★★★
Articles
exaly
›
Institutions
›
Hôpital Saint-Louis
›
Top Articles
Hôpital Saint-Louis
()
8.1K
(top 4%)
articles
304.7K
(top 3%)
citations
2,792
(top 3%)
★★
articles
147
(top 2%)
★★★
articles
2.8
(top 16%)
Avg IF
217
(top 2%)
H-Index
353
(top 2%)
G-Index
1,277
journals
Most Cited Articles of Hôpital Saint-Louis in 2020
Title
Journal
Year
Citations
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Science
2020
994
Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee
Journal of Clinical Immunology
2020
497
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Leukemia
2020
356
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Lancet Oncology, The
2020
281
Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification
Journal of Clinical Immunology
2020
267
Acute kidney injury in critically ill patients with COVID-19
Intensive Care Medicine
2020
226
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
New England Journal of Medicine
2020
160
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19
Blood
2020
147
Symptoms of burnout in intensive care unit specialists facing the COVID-19 outbreak
Annals of Intensive Care
2020
122
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Lancet Haematology,the
2020
116
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Lancet Haematology,the
2020
107
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Blood
2020
72
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
Journal of Clinical Oncology
2020
69
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Blood Advances
2020
58
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis
Rheumatology
2020
57
The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline
Intensive Care Medicine
2020
55
Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort
Clinical Microbiology and Infection
2020
55
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Leukemia
2020
54
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
Lancet Haematology,the
2020
52
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
Leukemia and Lymphoma
2020
50
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
American Journal of Hematology
2020
45
Synergistic effects of PRIMA-1 (APR-246) and 5-azacitidine in -mutated myelodysplastic syndromes and acute myeloid leukemia
Haematologica
2020
45
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Blood
2020
41
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
Lancet Haematology,the
2020
41
Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset
Intensive Care Medicine
2020
40
site/software ©
exaly
; All materials licenced under
CC by-SA
.